BlackRock Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

BlackRock Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$49.5M	Sell	671,795 -598,238	-47%	-$48.7M	0.06%	313
2016 Q3	$111M	Sell	1,270,033 -10,990	-0.9%	-$1.04M	0.14%	154
2016 Q2	$110M	Sell	1,281,023 -442,008	-26%	-$38.2M	0.14%	152
2016 Q1	$137M	Buy	1,723,031 +204,299	+13%	+$18.5M	0.18%	115
2015 Q4	$191M	Buy	1,518,732 +443,445	+41%	+$53.5M	0.24%	93
2015 Q3	$112M	Sell	1,075,287 -1,025,932	-49%	-$132M	0.15%	140
2015 Q2	$259M	Buy	2,101,219 +31,381	+2%	+$3.95M	0.32%	66
2015 Q1	$244M	Buy	2,069,838 +325,754	+19%	+$39M	0.32%	67
2014 Q4	$207M	Buy	1,744,084 +636,117	+57%	+$71.6M	0.27%	78
2014 Q3	$124M	Buy	1,107,967 +569,494	+106%	+$54.2M	0.17%	124
2014 Q2	$51M	Buy	538,473 +73,049	+16%	+$5.12M	0.07%	283
2014 Q1	$32.9M	Buy	465,424 +16,424	+4%	+$1.3M	0.05%	353
2013 Q4	$33.4M	Sell	449,000 -12,726	-3%	-$886K	0.05%	335
2013 Q3	$35M	Sell	461,726 -102,255	-18%	-$8.14M	0.06%	304
2013 Q2	$45.2M	Buy	+563,981	New	+$41.5M	0.08%	223

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's VRTX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 47% in Q4 2016, selling an estimated $48.7M and leaving 671,795 shares worth $49.5M. The position accounts for 0.06% of the portfolio, ranked #313.

BlackRock Investment Management first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $259M in Q2 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

BlackRock Investment Management held 671,795 shares of Vertex Pharmaceuticals worth $49.5M as of Q4 2016.
BlackRock Investment Management sold 598,238 Vertex Pharmaceuticals shares in Q4 2016, an estimated $48.7M.
Vertex Pharmaceuticals made up 0.06% of BlackRock Investment Management's portfolio in Q4 2016, its #313 holding.
BlackRock Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Vertex Pharmaceuticals position peaked at $259M in Q2 2015.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.